Literature DB >> 16652289

Recognition of Candida albicans by mannan-binding lectin in vitro and in vivo.

Joseph B Lillegard1, Robert B Sim, Peter Thorkildson, Marcellene A Gates, Thomas R Kozel.   

Abstract

Mannan-binding lectin (MBL) is a component of the innate immune system. The goal of the present study was to evaluate binding of MBL to Candida albicans in vitro and in vivo and to assess the impact of MBL treatment on host resistance. The results showed a variable and often discontinuous pattern of binding to individual yeast cells. MBL bound to cells grown at 37 degrees C but not to cells grown at 23 degrees C. The putative MBL ligand was constitutively present on yeast cells grown at 23 degrees C, but the ligand was masked on such cells, such that MBL could not bind. C. albicans yeasts and hyphae in infected tissue bound MBL. Finally, parenteral administration of MBL increased resistance of mice to hematogenously disseminated candidiasis. These results suggest that MBL is an important component of innate resistance to candidiasis and that MBL therapy may be a means to prevent disseminated candidiasis in high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16652289     DOI: 10.1086/503804

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

Review 2.  Anticandidal immunity and vaginitis: novel opportunities for immune intervention.

Authors:  Antonio Cassone; Flavia De Bernardis; Giorgio Santoni
Journal:  Infect Immun       Date:  2007-06-11       Impact factor: 3.441

Review 3.  Fungal killing by mammalian phagocytic cells.

Authors:  André Moraes Nicola; Arturo Casadevall; David L Goldman
Journal:  Curr Opin Microbiol       Date:  2008-06-21       Impact factor: 7.934

4.  Protective role of mannan-binding lectin in a murine model of invasive pulmonary aspergillosis.

Authors:  S Kaur; V K Gupta; S Thiel; P U Sarma; T Madan
Journal:  Clin Exp Immunol       Date:  2007-03-05       Impact factor: 4.330

Review 5.  Current understanding of fungal microflora in inflammatory bowel disease pathogenesis.

Authors:  David Underhill; Jonathan Braun
Journal:  Inflamm Bowel Dis       Date:  2008-08       Impact factor: 5.325

6.  Mannose-binding lectin levels and variation during invasive candidiasis.

Authors:  Sébastien Damiens; Julien Poissy; Nadine François; Julia Salleron; Samir Jawhara; Thierry Jouault; Daniel Poulain; Boualem Sendid
Journal:  J Clin Immunol       Date:  2012-07-26       Impact factor: 8.317

7.  Characteristics of Fc-independent human antimannan antibody-mediated alternative pathway initiation of C3 deposition to Candida albicans.

Authors:  Gayle M Boxx; Casey T Nishiya; Thomas R Kozel; Mason X Zhang
Journal:  Mol Immunol       Date:  2008-11-26       Impact factor: 4.407

8.  Mannose-binding lectin deficiency facilitates abdominal Candida infections in patients with secondary peritonitis.

Authors:  J W Olivier van Till; Piet W Modderman; Martin de Boer; Margreet H L Hart; Marcel G H M Beld; Marja A Boermeester
Journal:  Clin Vaccine Immunol       Date:  2007-10-31

9.  Binding of serum mannan binding lectin to a cell integrity-defective Cryptococcus neoformans ccr4Delta mutant.

Authors:  John C Panepinto; Kazimierz W Komperda; Moshe Hacham; Soowan Shin; Xiaoguang Liu; Peter R Williamson
Journal:  Infect Immun       Date:  2007-07-23       Impact factor: 3.441

10.  ELLSA based profiling of surface glycosylation in microorganisms reveals that ß-glucan rich yeasts' surfaces are selectively recognized with recombinant banana lectin.

Authors:  Luka Dragacevic; Brizita Djordjevic; Marija Gavrovic-Jankulovic; Vesna Ilic; Danijela Kanazir; Rajna Minic
Journal:  Glycoconj J       Date:  2019-12-10       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.